Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ACU-SERS

Financiado

Cerrado

AUTOMATED CLINICAL PLATFORM FOR PERSONALIZED ANTIBIOTHERAPY IN CRITICAL UNITS BA...

AUTOMATED CLINICAL PLATFORM FOR PERSONALIZED ANTIBIOTHERAPY IN CRITICAL UNITS BASED ON SURFACE ENHANCEMENT RAMAN SPECTROSCOPY Sepsis is a leading cause of death in hospitals resulting in ~700k deaths in Europe each year. Patients urgently require critical care and are admitted to an intensive care unit (ICU), where they are treated with antibiotics. Howe... ver más

30/04/2027

TECHNICAL UNIVERSI...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

DANMARKS TEKNISKE UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-05

HORIZON-EIC-2023-TRANSITIONCHALLENGES-01: EIC Transition Challenge: Full scal... Scope:The scope of the Challenge is the maturation of Micro-Nano-Bio technologies developed in previ...

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TECHNICAL UNIVERSITY OF DENM...

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

LUMABS Therapeutic antibody drug monitoring using bioluminescent se... 150K€ Cerrado

PeptIn employing protein aggregation as an antibacterial design str... 150K€ Cerrado

POC-TDM Development of a point-of-care microfluidic device for Thera... 158K€ Cerrado

PID2021-124867OB-I00 PROXIMA GENERACION DE DIAGNOSTICOS PARA COMBATIR LA RESISTEN... 214K€ Cerrado

HEMOSPEC Advanced spectroscopic hemogram for personalized care agains... 5M€ Cerrado

microMAGNETOFLUIDICS 3D printed magnetic microfluidics for applications in life s... 187K€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2024-03-05
Fecha Fin: 2027-04-30

Líder del proyecto

DANMARKS TEKNISKE UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Sepsis is a leading cause of death in hospitals resulting in ~700k deaths in Europe each year. Patients urgently require critical care and are admitted to an intensive care unit (ICU), where they are treated with antibiotics. However, antibiotic dosing is inappropriate in ~50% of sepsis patients, causing poor clinical outcomes due to increased adverse events, (neuro)toxicity and contributing to antibiotic resistance. Antibiotic dosing can be significantly improved through therapeutic drug monitoring (TDM), but current workflows for drug quantification in clinics and ICU are slow, expensive, and inflexible, which have greatly limited TDM implementation. We develop ACU-SERS: a first-in-class, highly flexible, fast, and cost-effective system that fully automates the biological sample pre-treatment, analyte separation and analysis and provides a quantitative antibiotic drug level concentration in ~15 minutes. ACU-SERS' breakthrough technology combines centrifugal microfluidics with an integrated surface-enhanced Raman spectroscopy (SERS) chip to perform label-free, rapid detection and quantification in an easy-to-use benchtop device. Based on the H2020 SERSing project, this project builds on developing the Raman-based analyser device and the optimal cartridge, as well as validating the scalability of the product and the system with clinical samples. From the commercial side, we will validate the commercial potential of our solution, found a spin-off company to commercialize the technology, and make it investment-ready. We envision that the spin-off will generate early revenues from direct sales in our initial target markets within the EU. After demonstrating market traction, we will seek to close a global distribution deal with a large diagnostics company for the TDM antibiotic market. Revenues will be reinvested to adapt ACU-SERS for TDM applications in other potential markets, such as antiepileptics, immunosuppressants and applications in pharmaceutical research.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores